

22nd August, 2025

**Shortage:
Hyoscine hydrobromide 1mg released over 72hours
transdermal patches**

Dear Colleagues,

Please note that there is a long-term supply issue with the UK licensed hyoscine hydrobromide (Scopoderm) 1mg released over 72hours patches.

For the management of hypersalivation or excessive respiratory secretions prescribers should consider other therapeutic options such as:

Hyoscine hydrobromide (Kwells) 150microgram and 300microgram tablets - titrate dose based on response and tolerability (off label indication). They are taken orally, sucked or chewed. In patients with swallowing difficulty, they can also be administered by sublingual or buccal route (off label route of administration).

Glycopyrronium bromide 1mg tablets and 1mg in 5ml oral solution - licensed for the symptomatic treatment of severe sialorrhoea (chronic pathological drooling/hypersalivation) in children and adolescents aged 3 years and older with chronic neurological disorders. Use in adults is off-label. They are an option if there is oral access/ patient can swallow.

For the management of travel or motion sickness use alternatives to hyoscine transdermal patches (see [TAM guidance](#)).

If none of the alternative options are appropriate, an unlicensed hyoscine hydrobromide 1mg transdermal patch may be available. This is likely to be a licensed product from another country. These may come from countries which use the term scopolamine instead of hyoscine. Scopolamine is a synonym for hyoscine i.e. scopolamine is the same drug as hyoscine and any product described as scopolamine hydrobromide can be used where hyoscine hydrobromide is prescribed. A photo of the product in current use across north NHS Highland hospitals is pictured below.



Kind regards
Medicines Management, Raigmore Pharmacy